The global Hunter Syndrome Treatment Market size is expected to reach a value of USD 1.52 billion by 2026, expanding at a CAGR of 7.1%, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period.
Hunter
syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare
genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase
enzyme. According to the data published by the National Institute of
Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every
100,000 to 150,000 male births.
Presently,
there are no approved curative therapies for the treatment of Hunter syndrome.
The available treatment options such as enzyme replacement therapy (ERT) and
hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic
relief and management of complications associated with disease progression. Shire
plc’s Elaprase (idursulfase) is the only key drug available for the treatment
of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta)
being approved only in South Korea.
Key
players are focused on extensive R&D activities for product development and
gaining approval as novel therapies. Launch of such novel therapies in the near
future is expected to significantly fuel the Hunter syndrome treatment market
growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track
designation for its novel drug candidate RGX-121, indicated for the disease
treatment.
Request
a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/hunter-syndrome-treatment-market
Further Key Findings from the Study Suggest:
- The enzyme
replacement therapy segment has acquired the largest share in 2018, owing
to the increased adoption of Elaprase and the potential approval of Hunterase
worldwide
- The absence
of curative therapies for MPS II creates lucrative opportunities for the
key players in the market for developing new therapies
- The launch
of late-stage pipeline therapies is expected to drive the market growth
during the forecast period
- Currently,
Shire Plc. is one of the leading players, supported by strong sales of
their marketed drug ELAPRASE for the disease treatment
- Major players
in the market are adopting inorganic growth strategies such as
partnerships and collaborations for the development and commercialization
of novel therapies
- In 2018,
North America held a dominant position in the global market, owing to
favorable reimbursement scenario, high awareness regarding rare disorders,
and presence of major players
- Some of the
key companies in hunter syndrome treatment market include GC Pharma,
Sangamo Therapeutics, Inc.; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.;
and Shire Plc. (Takeda Pharmaceutical Company)
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment